Response to HAART in treatment-naive HIV-infected patients with a prior diagnosis of tuberculosis or other opportunistic infections

Current HIV Research

Volumn 9, Issue 4, 2011, Pages 229-236

  Dronda, Fernando ^a   Sobrino Vegas, Paz ^b   Hernández Novoa, Beatriz ^a   Caro Murillo, Ana M ^b   Montero, Marta ^c   Iribarren, José A ^d   Sanz, Jesús ^e   del Mar Alonso, María ^f   Labarga, Pablo ^g   Bernal, Enrique ^h   Moreno, Santiago ⁱ  

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

^b CARLOS III INSTITUTE OF HEALTH   (Spain)

^c HOSPITAL UNIVERSITARIO LA FE   (Spain)

^d HOSPITAL DONOSTIA   (Spain)

^e HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^f HOSPITAL UNIVERSITARIO DE CANARIAS   (Spain)

^g HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^h HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

ⁱ Cohorte de la Red de Investigación en SIDA ^*  (Spain)

Author keywords

AIDS; AIDS defining illness; Antiretroviral therapy; HAART; HIV infection; Tuberculosis

Indexed keywords

ANTIRETROVIRUS AGENT;

ADOLESCENT; ADULT; AGED; AIDS DEFINING ILLNESS; ANAMNESIS; ANTIVIRAL ACTIVITY; ARTICLE; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; DEATH; ESOPHAGUS CANDIDIASIS; FEMALE; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; KAPOSI SARCOMA; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; OPPORTUNISTIC INFECTION; PNEUMOCYSTIS PNEUMONIA; RISK ASSESSMENT; TREATMENT DURATION; TREATMENT RESPONSE; TUBERCULOSIS; VIRUS INHIBITION; WASTING SYNDROME;

EID: 79959942242     PISSN: 1570162X     EISSN: 18734251     Source Type: Journal    
DOI: 10.2174/157016211796320324     Document Type: Article

References (30)

1. Moore RD, Chaisson RE. Natural history of HIV infection in the era of combination antiretroviral therapy. AIDS 1999; 13:1933-1942.
2. The CASCADE Collaboration. Survival after introduction of HAART in people with known duration of HIV-1 infection. Lancet 2000; 355:1158-1159.
3. Mocroft A, Lederberger B, Katlama C, et al. Decline in the AIDS and death rates in the EuroSIDA study: an observational study. Lancet 2003; 362: 22-29.
4. Walensky RP, Paltiel AD, Losina E, et al. The survival benefit of AIDS treatment in the United States. J Infect Dis 2006; 194: 11-19.
5. Castilla J, Sobrino P, de la Fuente L, Noguera I, Guerra L, Parras F. Late diagnosis of HIV infection in the era of highly active antiretroviral therapy: consequences for AIDS incidence. AIDS 2002; 16: 1945-1951.
6. Sabin CA, Smith CJ, Gumley H, et al. Late presenters in the era of highly active antiretroviral therapy: uptake of and responses to antiretroviral therapy. AIDS 2004; 18: 2145-2151.
7. Girardi E, Antonucci G, Vanacore P, et al. Impact of combination antiretroviral therapy on the risk of tuberculosis among persons with HIV infection. AIDS 2000; 14: 1985-1991.
8. Santoro-Lopes G, Felix de Pinho A, Harrison LH, Schechter M. Reduced risk of tuberculosis among Brazilian patients with advanced human immunodeficiency virus infection treated with highly antiretroviral therapy. Clin Infect Dis 2002; 34: 543-546.
9. Badri M, Wilson D, Wood R. Effect of highly antiretroviral therapy on incidence of tuberculosis in South Africa: a cohort study. Lancet 2002; 359: 2059-2064.
10. Ledergerber B, Egger M, Erard V, et al. AIDS-related opportunistic illnesses occurring after initiation of potent antiretroviral therapy: the Swiss HIV Cohort Study. JAMA 1999; 282: 2220-2226.
11. Kirk O, Gatell JM, Mocroft A, et al. Infections with Mycobacterium tuberculosis and Mycobacterium avium among HIV-infected patients after the introduction of highly active antiretroviral therapy. EuroSIDA Study Group JD. Am J Respir Crit Care Med 2000; 162: 865-872.
12. Jones JL, Hanson DL, Dworkin MS, et al. HIV-associated tuberculosis in the era of highly active antiretroviral therapy. The Adult/Adolescent Spectrum of HIV Disease Group. Int J Tuberc Lung Dis 2000; 14: 1985-1991.
13. Girardi E, Antonucci G, Vanacore P, et al. Tuberculosis in HIV infected persons in the context of wide availability of highly active antiretroviral therapy. Eur Respir J 2004; 24: 11-17.
14. Syler C, Toure S, Messou E, Bonard D, Gabillard D, Anglaret X. Risk factors for active tuberculosis after antiretroviral treatment initiation in Abidjan. Am J Respir Crit Care Med 2005; 172: 3-4.
15. Girardi E, Sabin CA, d'Arminio Monforte A and the Antiretroviral Therapy Cohort Collaboration. Incidence of tuberculosis among HIV-infected patients receiving highly active antiretroviral therapy in Europe and North America. Clin Infect Dis 2005; 41: 1772-1782.
16. Lawn SD, Badri M, Wood R. Tuberculosis among HIV-infected patients receiving HAART: long-term incidence and risk factors in a South African cohort. AIDS 2005; 19: 2109-2116.
17. Gutiérrez F, Padilla S, Masiá M, et al. Clinical outcome of HIVinfected patients with sustained virologic response to antiretroviral therapy: long-term follow-up of a multicenter cohort. PloS ONE 2006; 1:e89.
18. Rodríguez-Arenas MA, Jarrín I, Del Amo J, et al. Delay in the initiation of HAART, poorer virological response, and higher mortality among HIV-infected injecting drug users in Spain. AIDS Res Hum Retrovir 2006; 22: 715-723.
19. Gutiérrez F, Padilla S, Masiá M, et al. Patients' characteristics and clinical implications of suboptimal CD4 T-cell gains after 1 year of successful antiretroviral therapy. Curr HIV Res 2008; 6: 100-107.
20. Caro-Murillo AM, Castilla J, Pérez-Hoyos S, et al. Cohorte RIS de pacientes con infección por VIH sin tratamiento antiretroviral previo (CoRIS): metodología y primeros resultados. Enferm Infecc Microbiol Clin 2007; 25: 23-31.
21. Caro-Murillo AM, Gutiérrez F, Ramos JM, et al. Infección por virus de la inmunodeficiencia humana en inmigrantes en España: características epidemiológicas y presentación clínica en la cohorte CoRIS, 2004-2006. Enferm Infecc Microbiol Clin 2009; 27: 380-398.
22. Sobrino-Vegas P, García-San Miguel L, Caro-Murillo AM, et al. Delayed diagnosis of HIV infection in a multicenter cohort: prevalence, risk factors, response to HAART and impact on mortality. Curr HIV Res 2009; 7: 224-30.
23. Pape JW, Jean SS, Ho JL, Hafner A, Johnson WD Jr. Effect of isoniazid prophylaxis on incidence of active tuberculosis and progression of HIV infection. Lancet 1993; 342: 268-272.
24. Moreno S, Miralles P, Diaz MD, et al. Isoniazid preventive therapy in human immunodeficiency virus-infected persons. Long-term effect on development of tuberculosis and survival. Arch Intern Med 1997; 157: 1729-1734.
25. Lawn SD, Myer L, Bekker LG, Wood R. Tuberculosis-associated immune reconstitution disease: incidence, risk factors and impact in an antiretroviral treatment service in South Africa. AIDS 2007; 21: 335-341.
26. Velasco M, Castilla V, Sanz J, et al. Effect of simultaneous use of highly active antiretroviral therapy on survival of HIV patients with tuberculosis. J Acquir Immune Defic Syndr 2009; 50: 148-152.
27. Blanc FX, Havlir DV, Onyebujoh PC, et al. Treatment strategies for HIV-infected patients with tuberculosis: ongoing and planned clinical trials. J Infect Dis 2007; 196: S46-S51.
28. Karim SA, Naidoo K, Padayatchi N, et al. Optimal timing of ART during TB therapy: findings of the SAPiT trial. In: Programs and Abstracts of the 18th Conference on Retroviruses and Opportunistic Infections. Boston (MA), February-March 2011. [Abstract 39LB].
29. th Conference on Retroviruses and Opportunistic Infections. Boston (MA), February-March 2011. [Abstract 38].
30. Zolopa AR, Andersen J, Komarow L, et al. Early antiretroviral therapy reduces AIDS progression/death in individuals with acute opportunistic infections: A multicenter randomized strategy trial. PloS ONE 2009; 4: e5575.